Selective or targeted gene/drug delivery for liver tumors: Advantages and current status of local delivery

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 6, 2008, Pages 791-802

  Kim, Young Il ^a   Chung, Jin Wook ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Cancer; Delivery; Image guided procedure; Liver; Localized; Targeted; Therapy

Indexed keywords

ACETIC ACID; ALCOHOL; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; BRIVANIB ALANINATE; BROMOPYRUVIC ACID; CEDIRANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GRANULOCYTE COLONY STIMULATING FACTOR; HEXOKINASE; HEXOKINASE TYPE II; INTERLEUKIN 12; INTERLEUKIN 2; IODINATED POPPYSEED OIL; PLACEBO; RHENIUM 188; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; YTTRIUM 90;

ANTIANGIOGENIC THERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CRYOABLATION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG TARGETING; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; GENE TRANSFER; HUMAN; LIVER BLOOD FLOW; LIVER CANCER; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER TUMOR; LOCAL THERAPY; MICROWAVE THERAPY; NONHUMAN; RADIATION DOSE DISTRIBUTION; RADIOFREQUENCY ABLATION; REVIEW; TUMOR VASCULARIZATION; ARTIFICIAL EMBOLISM; GENE THERAPY; GENETICS; RADIOTHERAPY;

DRUG DELIVERY SYSTEMS; EMBOLIZATION, THERAPEUTIC; GENE THERAPY; HUMANS; LIVER NEOPLASMS; RADIOTHERAPY;

EID: 61549096099     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.6.791     Document Type: Review

References (83)

1. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 108, 390-401 (1988).
2. Rustgi VK. Epidemiology of hepatocellular carcinoma. Gastroenterol. Clin. North Am. 16, 545-551 (1987).
3. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56, 918-928 (1985).
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
5. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetime. J. Biol. Chem. 267, 18759-18765 (1992).
6. Sadauskas E, Wallin H, Stoltenberg M et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part. Fibre Toxicol. 19, 10 (2007).
7. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440-4445 (2000).
8. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14(5), 1310-1316 (2008).
9. Denny WA. Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Invest. 22(4), 604-619 (2004).
10. Choi BY, Chung JW, Park JH et al. Transfection efficiency of gene delivery to the rat liver using cationic lipid emulsion/DNA complex: comparison between IV, IA, and IP administration. Korean J. Radiol. 3, 194-198 (2002).
11. Anderson SC, Johnson DE, Harris MP et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin. Cancer Res. 4(7), 1649-1659 (1998).
12. Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics 28(1), 101-117 (2008).
13. +]: comparison between IV and intratumoral administration. J. Korean Radiol. Soc. 54, 103-112 (2006).
14. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res. 12(8), 2563-2567 (2006).
15. Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75, 589-596 (1974).
16. Kan Z, Ivancev K, Lunderquist A et al. In vivo microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to hepatic metastases. Radiology 187, 621-626 (1983).
17. Choi BI. Hepatocarcinogenesis in liver cirrhosis: imaging diagnosis. J. Korean Med. Sci. 13, 103-116 (1998).
18. Park YN, Yang CP, Fernandez GJ et al. Neoangiogenesis and sinusoidal 'capillarization' in DNs. Am. J. Surg. Pathol. 22, 656-662 (1998).
19. Wakasa K, Sakurai M, Kuroda C et al. Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 65, 913-919 (1990).
20. Goseki N, Nosaka T, Endo M et al. Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization. Cancer 76, 736-742 (1995).
21. Strohmeyer T, Haugeberg G, Lierse W. Angioarchitecture and blood supply of micro- and macrometastases in human livers. An anatomic-pathological investigation using injection techniques. J. Hepatol. 4, 181-189 (1987).
22. Taniguchi H, Daidoh T, Shioaki Y et al. Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling. Cancer 71, 50-55 (1993).
23. Sigurdson ER, Ridge JA, Kemeny N et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J. Clin. Oncol. 5, 1836-1840 (1987).
24. Embolization of liver tumors. In: Surgery of the Liver, Biliary Tract, and Pancreas (4th Edition). Blumgart LH (Ed.). Saunders, Philadelphia, PA, USA 1218-1245 (2007).
25. Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C. [L'embolisation arterielle hepatique dans les tumeurs malignes du foie.] Ann. Radiol. 17(6), 593-603 (1974).
26. Park JH, Han JK, Chung JW, Han MC, Kim ST. Postoperative recurrence of hepatocellular carcinoma: results of transcatheter arterial chemoembolization. Cardiovasc. Intervent. Radiol. 16, 21-24 (1993).
27. Lee HS, Kim KM, Yoon JH et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J. Clin. Oncol. 20(22), 4459-4465 (2002).
28. Konno T. Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 66, 1897-1903 (1990).
29. Nakamura H, Tanaka T, Hori S et al. Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in case of resection following embolization. Radiology 147(2), 401-405 (1983).
30. Okayasu I, Hatakeyama S, Yoshida T et al. Selective and persistent deposition and gradual drainage of iodized oil, lipiodol, in hepatocellular carcinoma after injection into the feeding hepatic artery. Am. J. Clin. Pathol. 90, 534-544 (1998).
31. Bhattacharya S, Novell JR, Winslet MC, Hobbs KEF. Iodized oil in the treatment of hepatocellular carcinoma. Br. J. Surg. 81, 1563-1571 (1994).
32. Yoon CJ, Chung JW, Park JH et al. Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229(1), 126-131 (2003).
33. Lewis AL, Gonzalez MV, Lloyd AW et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol. 17(2 Pt 1), 335-342 (2006).
34. Varela M, Real MI, Bruix J et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46(3), 474-481 (2007).
35. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. Radiat. Oncol. Biol. Phys. 53(4), 810-821 (2002).
36. Geschwind JF, Salem R, Carr BI et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127, S194-S205 (2004).
37. Murthy R, Nunez R, Szklaruk J et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25, S41-S55 (2005).
38. Liu MD, Uaje MB, Al-Ghazi MS et al. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am. Surg. 70(11), 947-953 (2004).
39. Kulik LM, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Salem R. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl. 11(9), 1127-1131 (2005).
40. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71-81 (2008).
41. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26(5), 1156-1161 (1997).
42. 188Rhenium-lipiodol solution: an experimental study in rabbit VX2 carcinoma. J. Vasc. Interv. Radiol. 15(10), 1121-1128 (2004).
43. Sundram F, Chau TC, Onkhuudai P, Bernal P, Padhy AK. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging 31, 250-257 (2004).
44. Bernal P, Raoul JL, Vidmar G et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int. J. Radiat. Oncol. Biol. Phys. 69(5), 1448-1455 (2007).
45. Orlacchio A, Bazzocchi G, Pastorelli D et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc. Intervent. Radiol. 31(3), 587-594 (2008).
46. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54(8), 1151-1156 (2005).
47. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 127(5 Suppl. 1), S218-S224 (2004).
48. Sala M, Llovet JM, Vilana R et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40, 1352-1360 (2004).
49. Lencioni R, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228, 235-240 (2003).
50. Avila MA, Berasain C, Sangro B, and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25(27), 3866-3884 (2006).
51. Gérolami R, Cardoso J, Bralet MP et al. Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery. Gene Ther. 5(7), 896-904 (1998).
52. Penuelas I, Mazzolini G, Boan JF et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128(7), 1787-1795 (2005).
53. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus - thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 60(15), 3989-3999 (2000).
54. Herraiz M, Beraza N, Solano A et al. Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum. Gene Ther. 14(5), 463-472 (2003).
55. Humphreys MJ, Ghaneh P, Greenhalf W et al. Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases. Gene Ther. 8, 1241-1247 (2001).
56. Mohr L, Shankara S, Yoon SK et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 31, 606-614 (2000).
57. Habib NA, Sarraf CE, Mitry RR et al. E1B-deleted adenovirus ( dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 12(3), 219-226 (2001).
58. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol. Ther. 8(1), 72-79 (2003).
59. Sun XY, Wu ZD, Hu JB. Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vivo. Hepatobiliary Pancreat. Dis. Int. 1(3), 373-377 (2002).
60. Kim YI, Chung JW, Park JH, Han JK, Hong JW, Chung H. Intraarterial gene delivery in rabbit hepatic tumors: transfection with nonviral vector by using iodized oil emulsion. Radiology 240(3), 771-777 (2006).
61. Maruyama K, Suzuki R, Takizawa T et al. Gene delivery by combination of novel liposomal bubbles with perfluoropropane and ultrasound. J. Control. Release 117(1), 130-136 (2007).
62. Shen ZP, Brayman AA, Chen L, Miao CH. Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery. Gene Ther. 15(16), 1147-1155 (2008).
63. Rumpold H, Wolf D, Koeck R, Gunsilius E. Endothelial progenitor cells: a source for therapeutic vasculogenesis. J. Cell. Mol. Med. 8, 509-518 (2004).
64. Prieto J, Fernandez-Ruiz V, Kawa MP, Sarobe P, Qian C. Cells as vehicles for therapeutic genes to treat liver diseases. Gene Ther. 15, 765-771 (2008).
65. Mazzolini G, Alfaro C, Sangro B et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol. 23, 999-1010 (2005).
66. Greiner EF, Guppy M, Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J. Biol. Chem. 269, 31484-31490 (1994).
67. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276, 43407-43412 (2001).
68. Shinohara Y, Ichihara J, Terada H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Lett. 291, 55-57 (1991).
69. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial-bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 1555(1-3), 14-20 (2002).
70. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 42(3), 358-364 (2004).
71. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 173, 83-91 (2001).
72. Park HS, Chung JW, Jae HJ et al. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. Korean J. Radiol. 8(3), 216-224 (2007).
73. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 62, 3909-3913 (2002).
74. Ko YH, Smith BL, Wang Y et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 324(1), 269-275 (2004).
75. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336 (1991).
76. Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Rev. Anticancer Ther. 5(4), 645-656 (2005).
77. Wu HP, Feng GS, Liang HM, Zheng CS, Li X. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J. Gastroenterol. 10(6), 813-818 (2004).
78. McDannold N, Fossheim SL, Rasmussen H et al. Heat-activated liposomal MR contrast agent: initial in vivo results in rabbit liver and kidney. Radiology 230, 743-752 (2004).
79. Dromi S, Frenkel V, Luk A et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin. Cancer Res. 13(9), 2722-2727 (2007).
80. Lee JM, Lee YH, Kim YK et al. Combined treatment of radiofrequency ablation and acetic acid injection: an in vivo feasibility study in rabbit liver. Eur. Radiol. 14(7), 1303-1310 (2004).
81. Qian C, Sangro B, Prieto J. New strategies to enhance gene therapy efficiency. Gastroenterology 123, 639-642 (2002).
82. Zender L, Köck R, Eckhard M et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 123(2), 608-618 (2002).
83. Nishikawa M. Development of cell-specific targeting systems for drugs and genes. Biol. Pharm. Bull. 28(2), 195-200 (2005).